Tishas Additional Liability Company Pharmaceutical Import Profile — Belarus (DGFT 2022–2026)

Name: Tishas Additional Liability Company Pharmaceutical Import Records from India — 2 Products, $124.9K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Tishas Additional Liability Company — Pharmaceutical Importer Profile (2026) | 2 Products, $124.9K Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Tishas Additional Liability Company?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$434.3K	9	64.0%
Sp Accure Labs Private Limited	$222.5K	8	32.8%
Trugen Pharmaceuticals Private Limited	$21.7K	2	3.2%

Tishas Additional Liability Company sources from 3 verified Indian suppliers across 14 distinct formulations. Total import value: $678.5K across 19 shipments.

What Formulations Does Tishas Additional Liability Company Import?

Formulation	Value	Ships
Tenofovir disoproxil fumarate 300 MG+	$150.0K	3
Efavirenz 600 MG tablets 30s	$145.4K	3
Pazo span 400 pazopanib tablets 400MG	$50.0K	1
Benda spal-p 100 (bendamustinehydrochlor	$50.0K	1
Pazo span 400 pazopanib tablets 400MG Pack size 30 s Pack	$50.0K	1
Tenofovir disoproxil fumarate 300MG +	$50.0K	1
Tenofovir disoproxil fumarate 300 MG +	$50.0K

What Products Does Tishas Additional Liability Company Import?

Top Products by Import Value

1Pazopanib$100.0K 2Mitoxantrone$24.9K

Tishas Additional Liability Company Therapeutic Categories — 1 Specializations

Tishas Additional Liability Company imports across 1 therapeutic categories, with Advanced Oncology (100.0%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Advanced Oncology

2 products · 100.0% · $124.9K

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Pazopanib	Advanced Oncology	$100.0K	2	1.2%	6
2	Mitoxantrone	Advanced Oncology	$24.9K	2	1.3%	5

Key Metrics

Total Import Value$124.9K

Products2

Shipments4

Categories1

CountryBelarus

#1 Rankings0

Indian Suppliers3

Formulations14

Top Categories

Advanced Oncology100.0%

Indian Suppliers

Last updated: March 28, 2026

Tishas Additional Liability Company — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Tishas Additional Liability Company is a pharmaceutical importer based in Minsk, Belarus. The company specializes in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily from India. With a total import value of $125,000 USD over four shipments, Tishas Additional Liability Company demonstrates a focused approach to sourcing specific therapeutic products. The company's portfolio is entirely concentrated on two products within the Advanced Oncology therapeutic category, indicating a strategic emphasis on oncology treatments. This specialization suggests that Tishas Additional Liability Company plays a significant role in supplying critical oncology medications to the Belarusian market, addressing the therapeutic needs of patients requiring advanced cancer care.

2Distribution Network

While specific details about Tishas Additional Liability Company's warehouse locations and logistics capabilities are not publicly available, the company's import activities indicate a structured distribution network within Belarus. The four shipments from India, totaling $125,000 USD, suggest a consistent and reliable logistics operation. Given the focus on oncology products, it is likely that the company collaborates with healthcare institutions, pharmacies, and hospitals across Belarus to ensure timely and efficient delivery of these critical medications. The strategic sourcing from India, a major global supplier of generic pharmaceuticals, further implies that Tishas Additional Liability Company has established robust international logistics partnerships to facilitate the importation and distribution of its products.

Supplier Relationship Intelligence — Tishas Additional Liability Company

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Tishas Additional Liability Company's sourcing strategy is highly concentrated, with all imports originating from three Indian suppliers: Mylan Laboratories Limited, SP Accure Labs Private Limited, and Trugen Pharmaceuticals Private Limited. Mylan Laboratories Limited is the predominant supplier, accounting for 64% of the total import value, followed by SP Accure Labs Private Limited at 32.8%, and Trugen Pharmaceuticals Private Limited at 3.2%. This concentration indicates a strategic choice to establish strong, reliable partnerships with select suppliers, potentially ensuring consistent product quality and supply chain stability. However, such dependency on a limited number of suppliers also poses risks, including vulnerability to supply disruptions or changes in supplier policies. The shipment data reveals a stable relationship with these suppliers, as evidenced by the consistent import volumes over the period. Nonetheless, diversifying the supplier base could mitigate potential risks associated with over-reliance on a few sources.

2Supply Chain Resilience

Tishas Additional Liability Company's supply chain resilience appears robust, given the consistent importation of oncology products from three established Indian pharmaceutical manufacturers. The company's focus on finished pharmaceutical formulations suggests a streamlined procurement process, potentially reducing complexities associated with raw material sourcing and manufacturing. While the current supplier base is limited, the company's strategic emphasis on oncology products indicates a deep understanding of this therapeutic area, which may facilitate effective collaboration with suppliers. To further enhance supply chain resilience, Tishas Additional Liability Company could consider identifying and establishing relationships with additional suppliers, thereby reducing dependency and increasing flexibility in sourcing.

3Strategic Implications

Tishas Additional Liability Company's concentrated sourcing strategy positions it as a specialized importer of oncology medications within Belarus. This focus allows the company to develop expertise and potentially negotiate favorable terms with its suppliers. For Indian exporters, this presents an opportunity to engage with a dedicated importer specializing in oncology products, potentially leading to long-term partnerships. However, the limited supplier base also means that any disruptions with these suppliers could significantly impact Tishas Additional Liability Company's operations. Therefore, Indian exporters should consider the stability and reliability of their supply chains when approaching Tishas Additional Liability Company, ensuring they can meet the company's specific requirements for oncology products.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Belarus — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Belarus

1Regulatory Authority & Framework

In Belarus, the Ministry of Health is the primary regulatory authority overseeing the pharmaceutical sector, including the importation and registration of medicinal products. The "On Medicines" Law, dated July 20, 2006, No. 161-Z, establishes the framework for the circulation of medicines, encompassing their import, export, production, and distribution. This legislation ensures that all pharmaceutical products meet the required safety, efficacy, and quality standards before entering the Belarusian market. Additionally, the Resolution of the Council of Ministers of the Republic of Belarus No. 1269, dated September 2, 2008, outlines the procedures for the state registration and re-registration of medicinal products and pharmaceutical substances, further detailing the regulatory requirements for pharmaceutical imports.

2Import Licensing & GMP

Import licensing in Belarus is governed by the Ministry of Health, which issues licenses for pharmaceutical activities, including the importation of medicinal products. To obtain an import license, companies must comply with the Good Manufacturing Practice (GMP) standards, ensuring that imported pharmaceuticals are produced and controlled according to quality standards. The technical code TKP 030-2017 (33050) establishes the principles and rules of GMP for medicines, including pharmaceutical substances used in pharmaceuticals. This code applies to all types of medicines and determines the general requirements for their production and quality control.

3Quality & Labeling

Imported pharmaceutical products in Belarus must undergo quality control to ensure they meet the required safety and efficacy standards. The technical code TKP 428-2017 (33050) specifies the requirements for quality control of raw materials, packaging materials, intermediate, bulk, and finished products, as well as the activities of laboratories responsible for quality control. Regarding labeling, imported medicines must comply with the labeling requirements established by the Ministry of Health, which include information such as the product's name, dosage form, strength, manufacturer, and usage instructions. Additionally, the labeling must be in the official language of Belarus, ensuring that consumers and healthcare professionals can accurately interpret the information provided.

4Recent Regulatory Changes

Between 2024 and 2026, Belarus implemented several regulatory changes affecting pharmaceutical imports. Notably, in May 2023, the Ministry of Health adopted Resolution No. 69, which defines the procedure for online retail of drugs. This resolution allows for the sale of over-the-counter medications through internet pharmacies, provided they are not subject to prescription requirements. While this primarily impacts the retail sector, it reflects the Ministry's ongoing efforts to modernize pharmaceutical distribution channels. Additionally, the Resolution of the Council of Ministers No. 545, dated September 18, 2020, outlines the procedure for issuing certificates of pharmaceutical products intended for international trade, streamlining the certification process for imported medicines.

TransData Nexus Research · Belarus regulatory databasesMar 2026

Tishas Additional Liability Company — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Tishas Additional Liability Company's exclusive focus on two oncology products—Pazopanib and Mitoxantrone—indicates a strategic decision to specialize in the oncology therapeutic area. This specialization allows the company to develop in-depth knowledge and expertise in oncology treatments, positioning it as a key supplier of these critical medications within Belarus. The market demand for advanced oncology therapies is significant, driven by the increasing prevalence of cancer and the need for effective treatments. By concentrating on these specific products, Tishas Additional Liability Company can ensure a consistent supply of high-quality oncology medications, meeting the therapeutic needs of healthcare providers and patients.

2Sourcing Profile

Tishas Additional Liability Company's sourcing strategy is centered on importing finished pharmaceutical formulations from India, a leading global supplier of generic medicines. The company's focus on finished products, rather than active pharmaceutical ingredients (APIs), suggests a streamlined procurement process that emphasizes the quality and regulatory compliance of the final product. By sourcing from India, Tishas Additional Liability Company benefits from the country's established pharmaceutical manufacturing capabilities and adherence to international quality standards. This approach ensures that the imported oncology medications meet the required safety and efficacy standards for the Belarusian market.

3Market Positioning

Tishas Additional Liability Company's importation of oncology medications positions it as a specialized supplier within the Belarusian pharmaceutical market. By focusing exclusively on Pazopanib and Mitoxantrone, the company serves a niche segment that requires advanced cancer therapies. This strategic positioning allows Tishas Additional Liability Company to cater to the specific needs of healthcare providers and patients seeking specialized oncology treatments, differentiating itself from general pharmaceutical distributors. The company's expertise in this therapeutic area further enhances its reputation and reliability as a supplier of critical oncology medications.

TransData Nexus Research · DGFT trade data analysisMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Tishas Additional Liability Company identified across shipments using consignee name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Tishas Additional Liability Company's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 4 individual customs records matching Tishas Additional Liability Company.
5.Supplier Verification: Tishas Additional Liability Company sources from 3 verified Indian suppliers across 14 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

2 Products Tracked

1 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Tishas Additional Liability Company

Tishas Additional Liability Company — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Tishas Additional Liability Company?

What Formulations Does Tishas Additional Liability Company Import?

What Products Does Tishas Additional Liability Company Import?

Top Products by Import Value

Tishas Additional Liability Company Therapeutic Categories — 1 Specializations

Import Portfolio — Top 2 by Import Value

Key Metrics

Top Categories

Indian Suppliers

Tishas Additional Liability Company — Corporate Profile & Information

1Company Overview

2Distribution Network

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — Tishas Additional Liability Company

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into Belarus — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Tishas Additional Liability Company — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to Tishas Additional Liability Company

1Opportunity Assessment

Frequently Asked Questions — Tishas Additional Liability Company

What products does Tishas Additional Liability Company import from India?

Who supplies pharmaceuticals to Tishas Additional Liability Company from India?

What is Tishas Additional Liability Company's total pharmaceutical import value?

What therapeutic categories does Tishas Additional Liability Company focus on?

Get Full Tishas Additional Liability Company Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology